Targeting STAT3 in cancer and autoimmune diseases
Copyright © 2020 Elsevier B.V. All rights reserved..
Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that is activated downstream of a broad range of receptors particularly interleukin-6 (IL-6) family. STAT3 is the key regulator of cell proliferation, survival and apoptosis and is constitutively activated in most human cancers, indicating that it can be an important potential therapeutic target for cancer treatment. STAT3 also has important roles in lymphocyte biology, regulation of immune responses and autoimmunity. Considering the vital role of STAT3 in tumor progression and autoimmunity, scientists have focused to develop small molecules that suppress STAT3 function. In this review, we firstly discussed the predominant role of STAT3 in cancer and autoimmune diseases. Subsequently, we discussed the efficacy and therapeutic potential of different STAT3 inhibitors in cancer and autoimmune diseases in preclinical studies and clinical trials offering an insight into novel approaches for development of new STAT3 inhibitors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:878 |
|---|---|
| Enthalten in: |
European journal of pharmacology - 878(2020) vom: 05. Juli, Seite 173107 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gharibi, Tohid [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.12.2020 Date Revised 17.12.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejphar.2020.173107 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308639502 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308639502 | ||
| 003 | DE-627 | ||
| 005 | 20231225132148.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejphar.2020.173107 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1028.xml |
| 035 | |a (DE-627)NLM308639502 | ||
| 035 | |a (NLM)32278856 | ||
| 035 | |a (PII)S0014-2999(20)30199-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gharibi, Tohid |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting STAT3 in cancer and autoimmune diseases |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.12.2020 | ||
| 500 | |a Date Revised 17.12.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
| 520 | |a Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that is activated downstream of a broad range of receptors particularly interleukin-6 (IL-6) family. STAT3 is the key regulator of cell proliferation, survival and apoptosis and is constitutively activated in most human cancers, indicating that it can be an important potential therapeutic target for cancer treatment. STAT3 also has important roles in lymphocyte biology, regulation of immune responses and autoimmunity. Considering the vital role of STAT3 in tumor progression and autoimmunity, scientists have focused to develop small molecules that suppress STAT3 function. In this review, we firstly discussed the predominant role of STAT3 in cancer and autoimmune diseases. Subsequently, we discussed the efficacy and therapeutic potential of different STAT3 inhibitors in cancer and autoimmune diseases in preclinical studies and clinical trials offering an insight into novel approaches for development of new STAT3 inhibitors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Autoimmune diseases | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a STAT3 | |
| 650 | 4 | |a Small molecule inhibitors | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a Interleukins |2 NLM | |
| 650 | 7 | |a Oligonucleotides |2 NLM | |
| 650 | 7 | |a STAT3 Transcription Factor |2 NLM | |
| 650 | 7 | |a STAT3 protein, human |2 NLM | |
| 650 | 7 | |a DNA |2 NLM | |
| 650 | 7 | |a 9007-49-2 |2 NLM | |
| 650 | 7 | |a Protein-Tyrosine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Babaloo, Zohreh |e verfasserin |4 aut | |
| 700 | 1 | |a Hosseini, Arezoo |e verfasserin |4 aut | |
| 700 | 1 | |a Abdollahpour-Alitappeh, Meghdad |e verfasserin |4 aut | |
| 700 | 1 | |a Hashemi, Vida |e verfasserin |4 aut | |
| 700 | 1 | |a Marofi, Faroogh |e verfasserin |4 aut | |
| 700 | 1 | |a Nejati, Kazem |e verfasserin |4 aut | |
| 700 | 1 | |a Baradaran, Behzad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of pharmacology |d 1967 |g 878(2020) vom: 05. Juli, Seite 173107 |w (DE-627)NLM000029769 |x 1879-0712 |7 nnns |
| 773 | 1 | 8 | |g volume:878 |g year:2020 |g day:05 |g month:07 |g pages:173107 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejphar.2020.173107 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 878 |j 2020 |b 05 |c 07 |h 173107 | ||